

AD _____

Award Number: W81XWH-12-1-0336

TITLE: Molecular innovations towards theranostics of aggressive prostate cancer

PRINCIPAL INVESTIGATOR: Xiankai Sun, PhD

CONTRACTING ORGANIZATION: University of Texas Southwestern Medical Center
Dallas, Texas 75390

REPORT DATE: September 2013

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) September 2013		2. REPORT TYPE Annual report		3. DATES COVERED (From - To) 1 September 2012-31 August 2013	
4. TITLE AND SUBTITLE Molecular innovations towards theranostics of aggressive prostate cancer				5a. CONTRACT NUMBER W81XWH-12-1-0336	
				5b. GRANT NUMBER W81XWH-12-1-0336	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Xiankai Sun				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Texas Southwestern Medical Center 2201 Inwood Rd., NE3.120A Dallas, Texas 75390				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES N/A					
14. ABSTRACT: In this project, we propose to develop a new drug delivery vehicle based on dendrimer nanotechnology for personalized medicine. This new class of nanoplatfoms contains imaging probe and molecular medicine with a cancer-specific targeting capability which is able to target cancer cells, monitor drug delivery and tumor response to achieve a "see and treat" strategy as a new concept of molecular medicine. Specifically, One Partner PI's lab will make dendrimers bearing functional handles to conjugate with chelating agents provided by the Initiating PI's lab for PET imaging and therapeutic peptides provided by another Partner PI's lab for the treatment of aggressive prostate cancer. In the 1 st year, the Initiating PI's lab has designed and synthesized the proposed bifunctional chelator scaffold system, CB-TE2A(¹ Bu) ₂ -N ₃ for the further construction of dendrimer-based theranostic agents for aggressive prostate cancer. In the meanwhile, the design concept has been extended to synthesize a bivalent imaging probe for quantitative PET imaging of PSMA expression in prostate cancer.					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON Xiankai Sun
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			19b. TELEPHONE NUMBER (include area code) 214-645-5978

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusion.....	6
References.....	6
Appendices.....	N/A

INTRODUCTION

This project combines the recent advances in prostate cancer (PCa) research from three different labs integrated with a strong interest and dedication to develop a new molecular medicine approach towards the eventual cure of PCa. Like other cancer types, the current available therapeutic regimens for metastatic PCa are not PCa specific. With respect to PCa cells harboring various genetic alterations, the development of small molecular agents targeting these genetic defects to achieve a better therapeutic efficacy is foreseeable. In this project, we propose to develop a new drug delivery vehicle based on dendrimer nanotechnology for personalized medicine. This new class of nanoplatforms contains imaging probe and molecular medicine with a cancer-specific targeting capability which is able to target cancer cells, monitor drug delivery and tumor response to achieve a “see and treat” strategy as a new concept of molecular medicine. This platform system will be flexible to adopt any new cell targeting molecule or any therapeutic agents. Specifically, Dr. Simanek’s lab will make dendrimers bearing functional handles to conjugate with chelating agents provided by Dr. Sun’s lab for PET imaging and therapeutic peptides provided by Dr. Hsieh’s lab for the treatment of aggressive PCa.

BODY

With the ultimate goal to generate a new class of dendrimer-based theranostic agents for aggressive PCa, we have arranged four Specific Aims as indicated in Statement of Work (SOW). Our work in the first year focused on Tasks 1 – 3 to accomplish **Aim 1** and **Aim 2**.

Aim 1: To construct dendrimer conjugates containing specific cell permeation peptides, peptide therapeutic(s) and a bifunctional chelator for PET imaging

Task 1 (Months 1 – 24): Synthesis and Characterization of Dendrimers - Scaffold Library

Please see Dr. Simanek’s annual report for the progress of this Task

Task 2 (Months 1 – 12): Synthesis & Characterization of CB-TE2A-based Bifunctional Chelator

As detailed below, my lab has developed an azide-modified form of CB-TE2A, CB-TE2A(^tBu)₂-N₃, which will conjugate with the alkyne-introduced dendrimers developed in Dr. Simanek’s lab.

Aim 2: To select potent compounds with screening systems based on specific mechanism(s) of action


Task 3 (Months 1 – 24). Selection of therapeutic peptides using high throughput assays

Please see Dr. Hsieh’s annual report for the progress of this Task

Task 2 (Months 1 – 12): Synthesis & Characterization of CB-TE2A-based Bifunctional Chelator

Fluorine-18 currently plays the dominating role in PET due to the great success of FDG (2-deoxy-2-¹⁸F-fluoro-D-glucose). However, its short half-life ($t_{1/2} = 109$ m) limits its applications to relatively big molecules and requires the radiochemical procedures be performed in the proximity of a cyclotron. Recently, a metal positron emitter, ⁶⁴Cu has drawn great interest in PET research due to its low positron range, availability, and reasonably long half life ($t_{1/2} = 12.7$ h), which enables its applications to a variety of molecules, such as peptides, antibodies/fragments,

and even nanoparticles.¹ Given the *in vivo* PK parameters and biodistribution profiles that we have obtained with the melamine-based dendrimers, ⁶⁴Cu is particularly suitable for the proposed role of tracking the peptide-dendrimer conjugate delivery in this project. The commonly used chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), can be used as the bifunctional chelator to label the conjugates with ⁶⁴Cu. Although DOTA-tris (t-Bu ester) is commercially available and can be conveniently used for the construction of DOTA-peptide conjugates, DOTA is not an optimal chelating agent for ⁶⁴Cu(II), a small metal ion that prefers an octahedral coordination environment.² As consequence, relatively high uptake in the liver or non-target organs is observed due to the transchelation of ⁶⁴Cu from DOTA to other serum proteins. In recent years, my group has focused on the evaluation of optimal chelating agents of Cu(II) for the application of copper radiopharmaceuticals.² Among the ligands evaluated, a bicyclo[6.6.2] tetraamine (CB-TE2A: 4,11-bis-(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2] hexadecane) was identified as an ideal chelating agent for the *in vivo* applications of copper radioisotopes. This ligand is capable of adopting conformations having all four nitrogen lone pairs convergent upon a cleft (*in, in* at the bridgehead nitrogens) for complexation of small hard metal ions. The crystal structure of Cu(II)-CB-TE2A reveals that Cu(II) is enveloped in the “clam-shell” of the cross-bridged ligand, where the Jahn-Teller distortions only amount to 2-3% of the Cu-N and Cu-O bond lengths³, while the axial Cu-O bonds of Cu(II)-TETA or -DOTA are elongated by 6-13% of the equatorial Cu-N bond lengths⁴. Thus, Cu(II) is well-protected from external attacks. *In vivo* evaluation ⁶⁴Cu-labeled CB-TE2A complexes has demonstrated that they are significantly more resistant to transchelation in liver and more rapidly cleared through non-target organs than currently used TETA/DOTA analogues.^{2a,2c,5} As such, we chose CB-TE2A to serve as the ⁶⁴Cu chelating core for the construction of dendrimer conjugates in this proposal. An azide-modified form of CB-TE2A, CB-TE2A(^tBu)₂-N₃, was designed to conjugate with the alkyne-introduced dendrimers via the well-established “click chemistry” procedure. The synthetic route to CB-TE2A(^tBu)₂-N₃ is outlined below.



Briefly, to the solution of **1** (0.050 g, 0.095 mmol) in dry acetonitrile (0.5 mL) was added triethyl amine (0.014 g, 0.142 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.027 g, 0.142 mmol). The resulting solution was stirred overnight at room temperature. The solvent was then removed under vacuum to afford the crude product, which was purified by HPLC (Elution time: 22 min) and the resulting fraction lyophilized to give **3** (0.040 g, 0.055 mmol, 58%) as a yellow viscous liquid. ¹H NMR (400 MHz, CDCl₃): δ 3.73-3.59 (m, 12H), 3.55 (m, 4H), 3.50-3.34 (m, 8H), 3.33-3.04 (m, 12H), 2.97-2.74 (m, 11H), 1.44 (s, 18H). MS (MALDI) *m/z* calcd for C₃₅H₆₆N₈O₈: 726.5; found: 727.8 ([M + H]⁺). Of note, the two internal carboxylate groups are kept protected with t-butyl so as to avoid the chelation of Cu(II), which might be resulted from the Cu(I) catalyst. To date, we have obtained > 100 mg of Compound **3** by four runs of the reaction.

KEY RESEARCH ACCOMPLISHMENTS

- We have designed and synthesized the proposed bifunctional chelator scaffold system, CB-TE2A(^tBu)₂-N₃.
- We have extended the chelator scaffold design for noninvasive assessment of prostate specific membrane antigen (PSMA) expression in prostate cancer.
- We have published two peer-reviewed papers: One is a review article that introduces our works-in-progress in the context of recent developments of dendrimer-based theranostic agents; the other is on the use of our proposed bifunctional chelator system to exploit the multivalent effect for the detection of PSMA.

REPORTABLE OUTCOMES

1. Lo S-T, Kumar A, Hsieh J-T, and Sun X: Dendrimer Nanoscaffolds for Potential Theranostics of Prostate Cancer with a Focus on Radiochemistry. *Molecular Pharmaceutics* **2013**, 10:793-812.
2. Hao G, Kumar A, Dobin T, Oz OK, Hsieh, J-T, and Sun X: A Multivalent Approach of Imaging Probe Design to Overcome an Endogenous Anion Binding Competition for Noninvasive Assessment of Prostate Specific Membrane Antigen. *Molecular Pharmaceutics*. **2013**, 10:2975-2985

CONCLUSION

We have designed and synthesized the proposed bifunctional chelator scaffold system, CB-TE2A(^tBu)₂-N₃ for the further construction of dendrimer-based theranostic agents for aggressive prostate cancer. In the meanwhile, we have extended the design concept to synthesize a bivalent imaging probe for quantitative PET imaging of PSMA expression in prostate cancer.

REFERENCES:

- (1) (a) Sun, X.; Anderson, C. *Methods Enzymol* 2004, 386, 237(b) Sun, X.; Rossin, R.; Turnler, J.; Becker, M.; Joralemon, M.; Welch, M.; Wooley, K. *Biomacromolecules* 2005, 6, 2541.
- (2) (a) Boswell, C. A.; Sun, X.; Niu, W.; Weisman, G. R.; Wong, E. H.; Rheingold, A. L.; Anderson, C. J. *J Med Chem* 2004, 47, 1465(b) Sprague, J. E.; Peng, Y.; Sun, X.; Weisman, G. R.; Wong, E. H.; Achilefu, S.; Anderson, C. J. *Clin Cancer Res* 2004, 10, 8674(c) Sun, X.; Anderson, C. J. *Methods Enzymol* 2004, 386, 237.
- (3) Wong, E. H.; Weisman, G. R.; Hill, D. C.; Reed, D. P.; Rogers, M. E.; Condon, J. S.; Fagan, M.; Calabrese, J. C.; Lam, K.-C.; Guzei, I. A.; Rheingold, A. L. *J. Am. Chem. Soc.* 2000, 122, 10561.
- (4) Riesen, A.; Zehnder, M.; Kaden, K. A. *Acta Cryst.* 1988, C44, 1740.
- (5) Sun, X.; Wuest, M.; Weisman, G. R.; Wong, E. H.; Reed, D. P.; Boswell, C. A.; Motekaitis, R.; Martell, A. E.; Welch, M. J.; Anderson, C. J. *J Med Chem* 2002, 45, 469.